

Attorney Docket No.: KUZ0032US.NP
Inventors: Hashimoto et al.
Serial No.: 10/584,739
Filing Date: June 26, 2006
Page 6

REMARKS

Claims 1-3, 7 and 11-15 are pending in the instant application. Claims 1-3, 7 and 11-15 have been rejected. Reconsideration is respectfully requested in light of the following remarks.

Rejections of Claims 1-3, 7 and 11-15 under 35 U.S.C 103(a)

Claims 1-3, 7 and 11-15 under been rejected under 35 U.S.C. 103(a) as being unpatentable over Tsuruda et al. (WO 01/68061 in view of Honda (U.S. Patent 5,637,293).

Claims 1-3, 7 and 11-15 have also been rejected under 35 U.S.C. 103(a) as being unpatentable over Tsuruda et al. (WO 01/68061) in view of Yasukochi et al. (U.S. Patent Application Publication No. 2005/0053646) has also been maintained.

Claims 1-3, 7 and 11-15 have also been rejected under 35 U.S.C. 103(a) as being unpatentable over US 2003/0109819 (hereinafter '819) in view of Tateishi (WO 03/037393).

Applicants respectfully traverse these rejections.

Claim 1 is drawn to a patch preparation comprising a support and an adhesive base, the adhesive base containing 8 to 50 mass % relative to total amount of the adhesive base of a rubber-system macromolecule having a double bond at least in a principal chain thereof and 0.1 to 10 mass %

Attorney Docket No.: KUZ0032US.NP
Inventors: Hashimoto et al.
Serial No.: 10/584,739
Filing Date: June 26, 2006
Page 7

relative to entire amount of the preparation of a nonsteroidal anti-inflammatory analgesic drug, and the adhesive base further containing 0.5 to 20 mass % relative to entire amount of the preparation of 4-tert-butyl-4'-methoxydibenzoylmethane as a stabilizer for the rubber-system macromolecule.

MPEP 2143.01 is clear; the mere fact that references can be combined or modified does not render the resultant combination obvious unless **>the results would have been predictable to one of ordinary skill in the art. *KSR International Co. v. Teleflex Inc.*, 550 U.S. ___, ___, 82 USPQ2d 1385, 1396 (2007).

A Declaration by Dr. Tsuruda submitted by Applicant's with the previous response filed March 15, 2010 in the instant patent application demonstrating unpredicted and/or unexpected advantages of a composition comprising 4-tert-butyl-4'-methoxydibenzoylmethane as compared to a composition comprising the hydroxybenzotriazole derivative Mexoryl® XL was suggested by the Examiner to be unpersuasive because it did not sufficiently compare the instant invention to the closest prior art. Further, the Examiner suggested that because the identity of the hydroxybenzotriazole derivative was not disclosed in the

Attorney Docket No.: KUZ0032US.NP
Inventors: Hashimoto et al.
Serial No.: 10/584,739
Filing Date: June 26, 2006
Page 8

declaration, no proper comparison could be made to what is taught by the prior art. In addition, the Examiner states that "given that these compounds belong to different classes of UV absorbents (e.g. dibenzoylmethane and hydroxybenzotriazole) it is not surprising (i.e. it is completely expected) that there may be differences in their behavior and efficiency."

Accordingly, in an earnest effort to advance the prosecution of this case, Applicants are providing herewith a supplemental Declaration by co-inventor Dr. Tsuruda evidencing more clearly the unpredicted and/or unexpected advantages of a composition comprising 4-tert-butyl-4'-methoxydibenzoylmethane as compared to a composition comprising the hydroxybenzotriazole derivative Mexoryl® XL.

Applicants respectfully direct the Examiner to paragraphs 3 and 4 of Dr. Tsuruda's Declaration wherein experiments comparing the effects of compositions containing ketoprofen and different UV blockers on ear swelling are described. As discussed in paragraph 3 of Dr. Tsuruda's Declaration, ear swelling is one of the side effects caused by decomposition products (i.e. radicals) of nonsteroidal antiinflammatory drugs (NSAIDs). In the comparative experiments performed, ethanol solutions containing 2% of

Attorney Docket No.: KUZ0032US.NP
Inventors: Hashimoto et al.
Serial No.: 10/584,739
Filing Date: June 26, 2006
Page 9

the NSAID ketoprofen and either 3% 4-tert-butyl-4'-methoxydibenzoylmethane (BM-DBM), or no UV blocker (referred to as controls) were applied to the ear of Balb/c mice (female, 9-11 weeks of age), followed by irradiation of 40 J/cm² of UVA (see paragraph 3 of Dr. Tsuruda's Declaration). The IUPAC name 2-(2H-benzotriazol-2-yl)-4-methyl-6-[2-methyl-3-[1,3,3,3-tetramethyl-1-(trimethylsilyl)oxy]disiloxanyl]propyl phenol) for Mexoryl® XL is also provided in paragraph 3 of Dr. Tsuruda's Declaration.

Results comparing measured thicknesses of the ears after 24 hours irradiation are shown in Figure 1 attached to Dr. Tsuruda's Declaration. As shown by Figure 1 and discussed in paragraph 4 of Dr. Tsuruda's Declaration, while both solutions containing UV blockers suppressed the increase in ear thickness indicative of swelling as compared to solutions containing no UV blocker (controls), 3% BM-DBM reduced ear swelling by about 55% compared to the controls while 3% Mexoryl® XL reduced ear swelling by only about 20% compared to the controls. Accordingly, BM-DBM was 2.75 times more effective at preventing photodecomposition of the NSAID ketoprofen to its radical form than the benzotriazole derivative Mexoryl® XL. See Figure 1 and paragraph 4 of Dr. Tsuruda's Declaration. From these experiments, Dr. Tsuruda

Attorney Docket No.: KUZ0032US.NP
Inventors: Hashimoto et al.
Serial No.: 10/584,739
Filing Date: June 26, 2006
Page 10

states in paragraph 4 that BM-DBM "is expected to be a significantly better stabilizer of the rubber system macromolecule than the benzotriazole derivative Mexoryl® XL."

MPEP 716.02(a) and the case law state "A greater than expected result is an evidentiary factor pertinent to the legal conclusion of obviousness ... of the claims at issue." *In re Corkill*, 711 F.2d 1496, 226 USPQ 1005 (Fed. Cir. 1985).

MPEP 716.02(a) and the case law also state "Applicants must further show that the results were greater than those which would have been expected from the prior art to an unobvious extent, and that the results are of a significant, practical advantage." *Ex parte The NutraSweet Co.*, 19 USPQ2d 1586 (Bd. Pat. App. & Inter. 1991).

A 2.75 fold increase in efficacy of a composition comprising BM-DBM at preventing photodecomposition of the NSAID ketoprofen to its radical form as compared to the benzotriazole derivative Mexoryl® XL as shown by Figure 1 and discussed in paragraph 4 of Dr. Tsuruda's Declaration is clearly a greater than expected result over cited teachings of Tsuruda et al. (WO 01/68061), US 2003/0109819, Yasukochi et al. (U.S. Patent Application Publication No.

Attorney Docket No.: KUZ0032US.NP
Inventors: Hashimoto et al.
Serial No.: 10/584,739
Filing Date: June 26, 2006
Page 11

2005/0053646) and Tateishi (WO 03/037393), none of which actually teach use of BM-DMA and Honda (U.S. Patent 5,637,293), which teaches BM-DBM to act equivalently to other UV blockers tested (see Tables 1 and 2 of Honda). Further, there is practical, significant advantage of these results, specifically that BM-DBM is expected to be a significantly better stabilizer of the rubber system macromolecule than the benzotriazole derivative Mexoryl® XL. See paragraph 4 of Dr. Tsuruda's Declaration.

MPEP 716.02(a) further states "Evidence of unobvious or unexpected advantageous properties, such as superiority in a property the claimed compound shares with the prior art, can rebut *prima facie* obviousness. Evidence that a compound is unexpectedly superior in one of a spectrum of common properties . . . can be enough to rebut a *prima facie* case of obviousness." Thus, the fact that BM-DBM and Mexoryl® XL are both UV blockers does not diminish this evidence of unobviousness based upon demonstrated clear superiority of BM-DBM in accordance with the instant claimed invention.

Also provided with Dr. Tsuruda's Declaration are absorption curves from two publicly available documents relating to the UV blockers Mexoryl® XL and avobenzone (also known as BM-DBM) and 2-(2-hydroxy-5-methylphenyl)

Attorney Docket No.: KUZ0032US.NP
Inventors: Hashimoto et al.
Serial No.: 10/584,739
Filing Date: June 26, 2006
Page 12

benzotriazole. See paragraph 5 of Dr. Tsuruda's Declaration. According to these curves, Mexoryl® XL and 2-(2-hydroxy-5-methylphenyl)benzotriazole have similar absorption curves. Accordingly, the experiments presented in Dr. Tsuruda's Declaration are predictive of how other benzotriazole derivatives such as the UV blocker 2-(2-hydroxy-5-methylphenyl)benzotriazole disclosed by Honda, as well as Tsuruda et al. (WO 01/68061), US 2003/0109819, would perform. See paragraph 5 of Dr. Tsuruda's Declaration. Thus, these experiments meet the requirements of MPEP 716.02(e) that the affidavit or declaration under 37 CFR 1.132 compare the claimed subject matter with the closest prior art, thereby effectively rebutting any *prima facie* case of obviousness. Also see *In re Burckel*, 592 F.2d 1175, 201 USPQ 67 (CCPA 1979). Applicants have appropriately compared the claimed UV blocker BM-DBM with a UV blocker Mexoryl® XL that is equally closely related to the UV blocker 2-(2-hydroxy-5-methylphenyl)benzotriazole disclosed in the prior art of Tsuruda et al. (WO 01/68061) and US 2003/0109819 and taught to be equivalent to BM-DBM by Honda. See *In re Holladay*, 584 F.2d 384, 199 USPQ 516 (CCPA 1978). MPEP 716.02(e) is clear; an applicant does not have to test all the compounds taught by each reference. Comparative

Attorney Docket No.: KUZ0032US.NP
Inventors: Hashimoto et al.
Serial No.: 10/584,739
Filing Date: June 26, 2006
Page 13

data presented in Dr. Tsuruda's Declaration clearly meets the requirements of MPEP 716,02(e), however, that where an applicant tests less than all cited compounds, *the test must be sufficient to permit a conclusion respecting the relative effectiveness of applicant's claimed compounds and the compounds of the closest prior art.*" *Id.* (quoting *In re Payne*, 606 F.2d 303, 316, 203 USPQ 245, 256 (CCPA 1979)) (emphasis in original).).

Also shown by the absorption curves provided with Dr. Tsuruda's Declaration is that the best effective absorption wavelength of avobenzone is longer than that of the two benzotriazole derivatives. Thus, contrary to the Examiner's assertion, avobenzone (BM-DBM) would not necessarily be expected by a skilled artisan to function in the same manner as Mexoryl® XL and 2-(2-hydroxy-4-methylphenyl)benzotriazole in transdermal patches based upon their differing absorption curves. See paragraph 5 of Dr. Tsuruda's Declaration. Clearly in no way would the claimed UV blocker BM-DBM be expected to function so much more effectively, specifically, 2.75 times more effectively, than the benzotriazole derivatives disclosed by cited references of Tsuruda et al. (WO 01/68061) and US 2003/0109819 and taught to be equivalent to BM-DBM by Honda.

Attorney Docket No.: KUZ0032US.NP
Inventors: Hashimoto et al.
Serial No.: 10/584,739
Filing Date: June 26, 2006
Page 14


The evidence submitted via this supplemental Declaration of superior and unexpected properties of the instant claimed invention rebuts any prima facie of obviousness over the cited combinations of references. See MPEP 2145.

Withdrawal of these rejections under 35 U.S.C. 103 is respectfully requested.

Conclusion

Applicants believe that the foregoing comprises a full and complete response to the Office Action of record. Accordingly, favorable reconsideration and subsequent allowance of the pending claims is earnestly solicited.

Respectfully submitted,


Kathleen A. Tyrrell
Registration No. 38,350

Date: September 30, 2010

LICATA & TYRRELL P.C.
66 E. Main Street
Marlton, NJ 08053
ktyrrell@licataandtyrrell.com
856-810-1515